Compound Detail
CHEMBL4594535
SUGEMALIMAB 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
No structure available
Basic Information
| ChEMBL ID | CHEMBL4594535 |
| Name | SUGEMALIMAB |
| Phase | Approved |
| Structure Type | NONE |
| Therapeutic | ✓ Yes |
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
6
Known Names
11
Indications
1
Mechanisms
Drug Information
| Molecule Type | Antibody |
| First Approval | 2024 |
| Availability | Unknown |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Programmed cell death 1 ligand 1 binding agent | BINDING AGENT | Programmed cell death 1 ligand 1 | ✓ | ✓ |
Indications
Carcinoma, Non-Small-Cell Lung Neoplasms Neoplasms Adenocarcinoma Esophageal Neoplasms Granuloma, Lethal Midline Stomach Neoplasms Hodgkin Disease Lymphoma Small Cell Lung Carcinoma Carcinoma, Hepatocellular
ATC Classification
L01FF11
sugemalimab
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: ANTINEOPLASTIC AGENTS
Data from ChEMBL 36 via Core Engine